# Silvia La Monica

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/silvia-la-monica/

## Facts

| Field | Value |
| --- | --- |
| Citations | 2,936 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 35 |
| i10-index | 59 |
| Last Known Institution | University of Parma |
| OpenAlex ID | https://openalex.org/A5043942287 |
| ORCID iD | 0000-0003-3578-3917 |
| Works | 96 |

## Researcher papers

- [Human myeloma cells stimulate the receptor activator of nuclear factor-κB ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease](https://scholariq.org/papers/human-myeloma-cells-stimulate-the-receptor-activator-of-nuclear-factor-b-ligand/)
- [The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells](https://scholariq.org/papers/the-anti-tumor-efficacy-of-cdk4-6-inhibition-is-enhanced-by-the-combination-with/)
- [Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells](https://scholariq.org/papers/combined-inhibition-of-cdk4-6-and-pi3k-akt-mtor-pathways-induces-a-synergistic/)
- [Multiple effects of CDK4/6 inhibition in cancer: From cell cycle arrest to immunomodulation](https://scholariq.org/papers/multiple-effects-of-cdk4-6-inhibition-in-cancer-from-cell-cycle-arrest-to/)
- [Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines](https://scholariq.org/papers/trastuzumab-emtansine-delays-and-overcomes-resistance-to-the-third-generation/)
- [Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones](https://scholariq.org/papers/overcoming-acquired-resistance-to-letrozole-by-targeting-the-pi3k-akt-mtor/)
- [Pre-treatment with the CDK4/6 inhibitor palbociclib improves the efficacy of paclitaxel in TNBC cells](https://scholariq.org/papers/pre-treatment-with-the-cdk4-6-inhibitor-palbociclib-improves-the-efficacy-of/)
- [Reprogramming of Lipid Metabolism in Lung Cancer: An Overview with Focus on EGFR-Mutated Non-Small Cell Lung Cancer](https://scholariq.org/papers/reprogramming-of-lipid-metabolism-in-lung-cancer-an-overview-with-focus-on-egfr/)
- [Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines](https://scholariq.org/papers/everolimus-restores-gefitinib-sensitivity-in-resistant-non-small-cell-lung/)
- [Cell size reduction induced by inhibition of the mTOR/S6K-signaling pathway protects Jurkat cells from apoptosis](https://scholariq.org/papers/cell-size-reduction-induced-by-inhibition-of-the-mtor-s6k-signaling-pathway/)
- [Resistance to osimertinib in advanced EGFR-mutated NSCLC: a prospective study of molecular genotyping on tissue and liquid biopsies](https://scholariq.org/papers/resistance-to-osimertinib-in-advanced-egfr-mutated-nsclc-a-prospective-study-of/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [PI3K/AKT/mTOR signaling in cancer](https://scholariq.org/topics/pi3k-akt-mtor-signaling-in-cancer/)
- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)

## Researcher university

- [University of Parma](https://scholariq.org/institutions/university-of-parma/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.